Select region:

Clinical trials located in


Namur city is located in Belgium. Currently, 20 clinical trials are being conducted in this city.

Namur, the capital of Wallonia, Belgium, is nestled at the confluence of the Meuse and Sambre rivers. This charming city is renowned for its strategic importance throughout history, evidenced by the imposing Citadel that has been a military fortification since Roman times. Namur is also celebrated for its vibrant cultural scene, hosting the annual International Francophone Film Festival. The city’s rich history is complemented by its picturesque medieval architecture, including the Saint Aubain Cathedral, a masterpiece of Baroque architecture.

  • CT-EU-00029960

    Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    BelgiumFranceGermanyGreeceHungaryItalyNetherlandsSpainUnited Kingdom
  • Testing safety and effects of telisotuzumab and docetaxel in Lung Cancer patients

    This study is for adults who have been treated before for a type of lung cancer called non-small cell lung cancer (NSCLC). The aim is to see if a new drug, called telisotuzumab vedotin, works better and is as safe as a common drug called docetaxel. In this study, cancer activity and any side-effects will be observed closely. The treatment will be given by a drip into a vein.The researchers will randomly decide whether each participant will get telisotuzumab vedotin or docetaxel, with an equal chance of getting either drug. While in the study, each person will have regular hospital or clinic visits to check how they are doing with tests and questionnaires.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Testing zimberelimab and domvanalimab with chemotheraphy for lung cancer

    This clinical trial explores the effectiveness of two new medicines, zimberelimab and domvanalimab, in tandem with chemotherapy for patients with untreated metastatic non-small cell lung cancer. The study’s main goal is to compare the impact and success of this combination treatment versus a control group receiving pembrolizumab along with chemotherapy. The hopeful outcome of the trial is to identify whether the new combination of drugs can provide enhanced benefits for the involved patients. Regular health monitoring will occur during the trial to ensure patient safety.

    AustriaBelgiumFranceGermanyItalyNetherlandsPortugalSpainUnited Kingdom
  • Exploring new treatment for advanced melanoma

    In this research, the researchers are examining a mix of fianlimab and cemiplimab as a potential treatment for a type of skin cancer called melanoma that is in an advanced stage or has spread to other parts of the body. It is important to see if this new medication is better than a current treatment, called pembrolizumab, in slowing down the growth of the disease. The main aim is to see how they respond to treatment, and the contribution of each drug in the mix. Additionally, the researchers will see if the drug triggers any reaction from the body’s immune system, assess how the two-drug regimen affects the patient’s physical activity, the role they play in their lives, overall health, and life quality.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • Examining povorcitinib for treating hidradenitis suppurativa

    This study is about a drug called Povorcitinib, also known as INCB054707. It’s being tested on people who have moderate to severe Hidradenitis Suppurativa (HS), a painful skin condition. The trial will last for 12 weeks, and then there will be an extension period of 42 weeks. The aim of the trial is to see whether the drug is both safe, and effective enough to reduce the symptoms by at least 50%, without increasing certain symptoms like abscesses or tunnels formed by the disease. The study will also look at whether the drug significantly reduces skin pain and improves quality of life.

  • Studying guanfacine treatment for ADHD

    This research focuses on investigating the medication Guanfacine hydrochloride (TAK-503) for individuals aged 6–17 years diagnosed with ADHD. The study is divided into two phases: initially comparing Guanfacine hydrochloride with another medication along with placebo. Subsequently, all participants will receive Guanfacine hydrochloride for an entire year. The primary objective is to determine whether Guanfacine hydrochloride can be beneficial for young individuals who have not responded to other ADHD treatments. Throughout the study, participants will engage in computer tests to assess cognitive functions such as processing speed, memory, and learning abilities. Changes in participants’ physical characteristics, such as height and weight, will be measured due to potential effects of the medication. Additionally, the study aims to understand if Guanfacine hydrochloride has an impact on the mood or sleepiness of the participants, and parents will provide relevant information by answering specific questions.

    AustriaBelgiumGermanyNetherlandsPortugalSpainSwedenUnited Kingdom
  • Examining the impact of 2LHERP® on recurrent herpes

    This is a study to test a medication called 2LHERP for treating sores caused by a common virus named Herpes in the mouth and face area. 2LHERP will be compared with a placebo, which looks like 2LHERP but doesn’t have any medicine in it. 2LHERP has been available for over 20 years and has shown to be useful in treating these sores by controlling the body’s immune response. Now, in this trial, doctors want to study more on how effective it really is in treating these sores. The main goal is to see if 2LHERP can reduce the number of times these sores reappear over 12 months.

  • Study testing Ruxolitinib cream for Prurigo Nodularis treatment

    This study is testing a cream with Ruxolitinib to see if it’s safe and effective for people with a skin condition called Prurigo Nodularis (PN). The study has three main parts. In the first 12 weeks, participants will receive either the cream with Ruxolitinib or placebo (also known as vehicle-controlled) treatment. After that, all participants will receive the cream with Ruxolitinib for another 40 weeks. After that, there will be an extra 30 days to keep an eye on safety. The trial will measure success by checking if the cream can reduce itchiness. Treatment success will be evaluated by medical professionals, considering factors such as the number of skin nodules and the extent of redness and crusting in the condition’s severity.

  • Study to test targeted therapy for invasive lobular breast cancer

    This research study is for people with Invasive Lobular Carcinoma of the Breast (ILBC). This type of cancer is mostly treated like another type called Invasive Ductal Breast Carcinoma (IDBC) even though ILBC has different characteristics. The study is exploring whether a certain drug might help treat it. This particular study will evaluate a drug known as Entrectinib combined with another drug called letrozole (and also goserelin for women who have not been through menopause). The treatment will take place before any surgery (called neoadjuvant therapy) and will last for 4 months. The goal is to see if these drugs can reduce the size of the cancer before surgery.

  • Blood pressure study of a new drug in narcolepsy

    This study is all about testing a different medication for people who have narcolepsy, a sleep disorder. Currently, many people with narcolepsy take a medicine called ‘high-sodium oxybate’. But, this study wants to see what happens if patients switch to a different medication, called Sodium Oxybate/Potassium Oxybate/Calcium Oxybate/Magnesium Oxybate (JZP258), which has less sodium in it. Sodium can affect your blood pressure, so the researchers would like to check how everyone’s blood pressure changes after switching to the new medicine. This information could be super useful for doctors and patients because it helps everyone understand how the amount of sodium in the medication can impact a patient’s health.

  • Inavolisib & Phesgo treatment for metastatic breast cancer

    This study aims to assess the effectiveness of a new drug, inavolisib, in individuals with a type of advanced breast cancer characterized by a specific gene mutation—PIK3CA-mutated and HER2-Positive. The investigation focuses on cases where cancer has metastasized to other parts of the body. The combination of inavolisib with another treatment, Phesgo, will be examined, and outcomes will be compared between those receiving this combination and those who only receive Phesgo along with a placebo—a treatment resembling inavolisib but lacking any medication. This study is part of a Phase III, signifying an extensive evaluation of the treatment following promising results in previous smaller tests.

  • Testing ADT with or without darolutamide in prostate cancer patients

    This study is about testing how well two different kinds of prostate cancer treatment work. One treatment is called ADT (Androgen deprivation therapy) and the other is called darolutamide. In total, around 300 men who have just been diagnosed with prostate cancer will take part. The people in the study will be split into two groups. Half of the people will have the ADT treatment with placebo, while the other half will have both the ADT and darolutamide treatment. This will help the researchers understand whether adding darolutamide makes the ADT treatment work better. To check how well the treatment is working, the researchers will be using different methods.

  • Exploring magrolimab use for head and neck tumors

    This is a study about treatment of patients with squamous cell carcinoma, a type of head and neck cancer. The study will test the safety and effectiveness of a drug called magrolimab, used together with other cancer treatments. The study wants to know how well the treatment works. Throughout the trial, participants’ health will be closely monitored. This includes regular medical check-ups, imaging tests, and other diagnostic procedures to assess how well the cancer is responding to the treatment regimen.

    BelgiumFranceGermanyItalyPolandPortugalSpainUnited Kingdom
  • Testing a treatment for Human Papilloma Virus

    This experiment involves the use of a medication known as 2LPAPI to treat infections caused by HPV, a widespread virus. The primary objective of this study is to assess the effectiveness of 2LPAPI in treating HPV infections specifically located in the genital areas of women. The study spans a 4-year timeframe, during which doctors will closely monitor the infection to evaluate the medicine’s efficacy. The study protocol includes a main treatment period lasting for 6 months, during which the participants will receive the medication. Subsequently, doctors will continue to track the infection for an additional 6 months. The study is seeking women aged between 25 and 45 who exhibit irregularities in their cervix during regular check-ups.

  • Inupadenant study in second-line non-small cell lung cancer

    This clinical trial aims to explore the potential of inupadenant (EOS100850) when combined with standard chemotherapy drugs, carboplatin and pemetrexed, in treating advanced non-small cell lung cancer in adults. The study is particularly focused on patients for whom previous immunotherapy treatments were not successful.

    The trial has two primary goals. Initially, it seeks to determine the most effective and safest dose of inupadenant when used alongside chemotherapy. Once the optimal dosage is established, the next phase involves comparing the treatment’s effectiveness against a placebo, in combination with the chemotherapy drugs.

    Throughout the study, participants’ health and responses to the treatment are closely monitored.

  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Testing Retifanlimab alone or combined in advanced endometrial cancer

    This research is all about testing a medication called retifanlimab for people who have a late stage of endometrial cancer that’s not improving as desired with a standard drug treatment. This cancer affects the womb lining, and is more severe when it spreads to other body parts. The investigation aims to assess the efficacy of retifanlimab, both as a standalone treatment and in combination with other therapies, to identify the most effective approach to aid individuals grappling with this illness. Monitoring includes tracking the progression of your disease, assessing the duration of your body’s response to the treatment, and observing for any potential side effects or new symptoms that may arise after initiating the new drug.

  • Evaluating two drug combinations for advanced breast cancer

    This study is examining two different drug combinations for treating a specific type of breast cancer. The primary aim is to assess the comparative effectiveness and safety of these combinations. One combination uses the drugs lasofoxifene and abemaciclib, and the other uses fulvestrant and abemaciclib. The patients for this trial are men and women who have already been treated for breast cancer that has spread or cannot be removed by surgery, is positive for estrogen receptors (ER+), does not over-produce a growth factor (HER2-), and has a specific genetic mutation (ESR1).

    BelgiumCzechiaFranceGermanyHungaryItalyPolandRomaniaSpainUnited Kingdom
  • Sacituzumab trial for metastatic breast cancer patients

    This study is all about trying a medication named Sacituzumab Govitecan for individuals with a specific kind of breast cancer that has spread beyond the breast (metastatic) and is not affected by certain hormones or proteins. The goal is to see if this medicine can help people live longer by stopping the cancer from growing or spreading. This medicine will be compared with other usual treatments that your doctor may choose, such as paclitaxel or capecitabine. The study also aims to know the percentage of patients who see their cancer shrink as a result of the treatment. Furthermore, the study will also evaluate how the treatment impacts the overall well-being of the patients, through a series of questions related to physical, emotional, and social life.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyPolandPortugalSpainUnited Kingdom

See more clinical trials in other cities in Belgium: